Pharmaceuticals
Our global Pharmaceuticals portfolio includes more than 45 key marketed products, many of which are leaders in their respective therapeutic areas. We have received 17 new pharmaceutical product approvals in the US since 2000, the most of any pharmaceutical company.
Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.
Click on the product link where available to display complete product information. Please note that some product links are intended for US residents only.
A-Z
A C D E F G L M N P R S T V X Z
Elidel
Atopic dermatitis (eczema)
Visit www.elidel.com (US residents only)
Enablex/ Emselex
Overactive bladder
Visit www.enablex.com (US residents only)
Estraderm TTS/ Estraderm MX
Estrogen deficiency
Estragest TTS
Estrogen deficiency in postmenopausal women
Eucreas (single tablet combination of Galvus and metformin)
Approved in EU for type 2 diabetes
Exelon/Exelon Patch (rivastigmine tartrate)
Alzheimer’s disease and mild to moderate dementia associated with Parkinson’s disease
Visit www.exelon.com (US residents only)
Exforge (valsartan and amlodipine besylate)
Hypertension
Visit www.exforge.com (US residents only)
Exjade (deferasirox)
Chronic iron overload in transfusion-related conditions
Visit www.exjade.com
Pharmaceuticals business at Novartis
Novartis discovers and develops innovative medicines with improved efficacy and fewer side-effects.
Latest news
Patient groups
Our commitment to high-quality healthcare has led to an enduring and trusted partnership between Novartis and various patient groups.